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Abstract: Disease-specific fears predict health status in chronic obstructive pulmonary disease (COPD),
but their role in pulmonary rehabilitation (PR) remains poorly understood and especially longer-term
evaluations are lacking. We therefore investigated changes in disease-specific fears over the course
of PR and six months after PR, and investigated associations with PR outcomes (COPD assessment
test (CAT) and St. Georges respiratory questionnaire (SGRQ)) in a subset of patients with COPD
(n = 146) undergoing a 3-week inpatient PR program as part of the STAR study (Clinicaltrials.gov, ID:
NCT02966561). Disease-specific fears as measured with the COPD anxiety questionnaire improved
after PR. For fear of dyspnea, fear of physical activity and fear of disease progression, improvements
remained significant at six-month follow-up. Patients with higher disease-specific fears at baseline
showed elevated symptom burden (CAT and SGRQ Symptom scores), which persisted after PR and
at follow-up. Elevated disease-specific fears also resulted in reduced improvements in Quality of Life
(SGRQ activity and impact scales) after PR and at follow-up. Finally, improvement in disease-specific
fears was associated with improvement in symptom burden and quality of life. Adjustment for
potential confounding variables (sex, smoking status, age, lung function, and depressive symptoms)
resulted in comparable effects. These findings show the role of disease-specific fears in patients with
COPD during PR and highlight the need to target disease-specific fears to further improve the effects
of PR.
Keywords: disease-specific fears; COPD; pulmonary rehabilitation; anxiety
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition characterized
by airflow obstruction, mainly due to inflammatory lung pathology caused by exposure to cigarette
smoke or other noxious particles and gases [1]. Common symptoms of COPD include dyspnea, cough,
sputum production, wheezing, and chest tightness, which are associated with a significant individual,
social, and economic burden [1].
Pulmonary rehabilitation (PR) is an effective and evidence-based intervention for COPD [1]. PR is
a multidisciplinary treatment strategy, which consists of exercise training, respiratory physiotherapy,
smoking cessation, and patient education as key components, with the goal of behavior change realized
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through encouraging self-efficacy [2]. PR has been shown to improve exercise capacity, dyspnea,
emotional functioning, as well as health-related quality of life [3,4]. Nevertheless, key questions remain
about the essential components and mediating mechanisms of PR as well as on the long-term efficacy
of PR in accomplishing and maintaining behavior change [4,5].
Anxiety and depression are highly prevalent in patients with COPD, with prevalence estimates
ranging from 10% to 50% [6–11]. Furthermore, these psychological disorders are often underdiagnosed
and undertreated in patients with COPD [8,12,13]. High levels of anxiety and depression are associated
with reduced quality of life [14], increased costs to the healthcare system [15,16], and increased
mortality [17,18]. Furthermore, anxiety and depression are associated with reduced functional exercise
capacity and increased dyspnea [19,20], increased hospitalizations and COPD exacerbations [21–24],
as well as unfavorable health behaviors including reduced self-reported medication adherence [25],
and increased levels of smoking and physical inactivity [26].
Most previous studies on anxiety and COPD have only examined general forms of anxiety,
irrespective of its link to COPD. However, researchers have started to explore the role of disease-specific
fears and anxiety in COPD [27,28], which may be more closely related to relevant symptoms and
behaviors in COPD, and therefore provide a target for more specific interventions [29,30]. In the
field of chronic pain, this approach has led to a greater understanding of the sensation of pain and
pain-related disability, and has spurred interventions aimed at reducing pain-related fear [31,32].
Recent findings in COPD show that worse dyspnea-related anxiety and fear of physical activity are
associated with indicators of symptom severity, quality of life, exercise capacity, and even structural
brain changes [29,30,33–38]. Other fears identified in patients with COPD include fear of social
exclusion, fear of disease progression and sleep-related worries [33]. All five categories have shown
associations with disease-specific disability, and provide incremental predictive value above measures
of general negative affect (anxiety and depression) [30].
Disease-specific fears may help or hinder currently available treatments for COPD. Qualitative
studies have suggested that disease-specific fears interfere with self-management of COPD and are
associated with concerns about participation in pulmonary rehabilitation [28,39]. Furthermore, several
studies have reported that symptom-specific fears can improve during PR [37,40–44], whereas there
is suggestive evidence that symptom-specific fears remain stable in usual care [40]. These findings
would fit with an interpretation that repeated exposure to physical activity during PR would reduce
disease-specific fears, especially fear of dyspnea and fear of physical activity. However, knowledge on
the maintenance of these changes after rehabilitation is currently lacking, but would offer insight into
the role of disease-specific fears in maintaining improved PR outcomes.
A related question is whether disease-specific fears at the start of PR help or hinder the outcome
of rehabilitation. There are some initial findings that individuals starting PR with higher levels of fear
of dyspnea and fear of physical activity show greater improvements in exercise capacity during PR,
as well as a greater reduction in exercise-induced dyspnea and emotional burden [36]. Furthermore,
participants characterized by greater activity limitations and fear of dyspnea but less severe airway
obstruction show largest improvements after PR [40]. However, other contrasting findings suggest that
disease-specific fears at baseline show persistent negative associations with PR outcomes including
health status, quality of life, and 6 min walking distance, even after participation in PR [37,43–45],
but investigations into associations of disease-specific fears with longer-term outcomes are still lacking.
With this study, we therefore aimed to investigate longer-term changes in disease-specific fears
in PR participants with COPD as well as associations of disease-specific fears with PR outcomes.
In accordance with previous findings, we expected a reduction in disease-specific fears over the course
of a three-week inpatient PR. Furthermore, we expected these reductions to be maintained at six-month
follow-up. Finally, we investigated the effects of baseline levels of disease-specific fears on PR outcome
trajectories as well as the association of within-individual change in disease-specific fears on changes
in PR outcomes, with symptom burden measured using CAT designated as the main outcome variable.
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2. Experimental Section
2.1. Participants
Participants were the initial 146 participants who had completed participation in a larger,
controlled trial of pedometer based behavioral intervention as an add-on to PR for COPD (STAR
Study, Trial registration Clinicaltrials.gov, ID: NCT02966561. [46]). Data from these 146 participants
consisted a first data release from the STAR Study investigators, with data blinded for group allocation.
The study protocol was approved by the independent Research Ethics Committee of the Medical
Faculty of Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany (Ref. No. 321_15B). The main
inclusion criterion was an ICD-10 diagnosis of COPD, confirmed by lung function (FEV1/FVC < 0.7
after bronchodilatory medication). Main exclusion criteria were severe comorbidity (e.g., cancer or
severe cardiac or neurological comorbidities, severe psychiatric condition), considerable reduction of
sight or hearing, or an inability to speak German [46].
2.2. Pulmonary Rehabilitation Program
Patients completed a three-week inpatient PR program. The PR program consists of obligatory
elements (medication review, structured COPD patient education with practical training of correct
inhalation technique (“device training”), endurance and strength exercise, whole body vibration
training, and respiratory physiotherapy), with a main focus on exercise training. Additional optional
elements included a comprehensive smoking cessation program, psychological interventions and
social counseling, nutritional counseling, mucolytic physiotherapy, inspiratory muscle training, saline
inhalation therapy, patient education regarding long-term oxygen use, and occupational therapy.
Participants were randomized to receive either information on physical activity and physical activity
exercises (control group), or a pedometer assisted intervention focused on instruction (how to perform
monitoring and physical activity), monitoring, goal setting, and feedback (intervention group). For full
details of the program, including a list of behavior change techniques employed by both treatment
arms, see [46].
2.3. Measurements
2.3.1. Lung Function and Exercise Capacity
Spirometry was performed in accordance with ERS/ATS guidelines [47], using reference values
from the Global Lung Initiative [48]. Forced Expiratory Volume in 1 s (FEV1) and Vital Capacity (VC)
were extracted as variables of interest.
The Six-Minute Walking Test (6MWT) was performed to evaluate the functional exercise capacity
of the participants. The test was carried out on a 30 m track, in accordance with ATS guidelines [49].
However, a single test was performed as research in the context of a previous trial showed no added
benefit of duplicate testing [50]. After 6 min, walking distance of participants was recorded. The test
has appropriate reliability and validity for evaluation of exercise capacity in the context of PR [51].
2.3.2. Self-Report Measures
The validated COPD Angst Fragebogen (CAF; COPD Anxiety Questionnaire, [33] was used
to measure the disease-specific fears in patients with COPD. The CAF is a 27-item questionnaire,
consisting of five subscales: fear of social exclusion (FSE) (eight items), fear of dyspnea (FD) (five
items), fear of physical activity (FPA) (six items), fear of disease progression (FP) (six items), and sleep
related worries (SRW) (two items). Each item is scored on a five-point Likert scale, from 0 (never)
to 4 (always), with higher scores indicating higher levels of disease-specific fears. Two additional
subscales related to long-term oxygen therapy and to partnership were assessed but not included
in analyses, because these were not applicable for many patients. So far, no analysis of minimum
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clinically important differences (MCIDs) have been conducted for the CAF. Therefore, standardized
mean differences (Cohen’s d) are presented below when discussing changes in CAF scores.
The COPD assessment test (CAT, [52]) was used as a measure of health status. The CAT consists of
eight items assessing symptoms, activity limitations, and impact of COPD with answer scores ranging
from 0 (no impairment) to 5 (maximal impairment). It is a brief instrument with good reliability and
validity [53,54]. The MCID for the CAT ranges from 2 (anchor based) to 3.8 (distribution based) [54],
with a pooled estimate of 3.29 in a German PR population [55].
The impact of dyspnea on daily activities in patients with COPD was evaluated using the German
self-administered version of the baseline dyspnea index (BDI) and the transition dyspnea index
(TDI) [56–58]. Both the BDI and the TDI are composed of three domains: functional impairment,
magnitude of task, and magnitude of effort. The BDI measures the perceived severity at a single point
in time and is the initial baseline assessment. The score on the BDI ranges from 0 (most severe level)
to 12 (least physical limitation). The TDI measures change in comparison to the baseline assessment.
Scores on the TDI range from −9 (more deterioration) to +9 (amelioration). The German versions of
the BDI and the TDI maintain their concurrent and construct validity and can be used to evaluated
changes in activity-related dyspnea in patients with COPD [56,57].
The St. Georges respiratory questionnaire (SGRQ, [59]) was used to measure the health-related
quality of life (HRQoL) in patients with COPD. The SGRQ is a valid and reliable instrument to
measure the self-reported health impairment and HRQoL in COPD patients [53]. The SGRQ consists
of three subscales. The impact subscale measures social functioning and psychological disturbances
resulting from airway disease; the symptoms subscale measures the effect of respiratory symptoms,
their frequency and severity; and the activity subscale looks at activities that cause or are limited by
dyspnea. Scores represent a percentage of overall impairment where 0 represents the best possible
HRQoL and 100 the worst possible HRQoL.
Depressive symptoms were measured using the Patient Health Questionnaire depression scale
(PHQ-9) [60]. This questionnaire consists of nine questions; each scored on a scale ranging from 0 (not
at all) to 3 (nearly every day). The total score ranges from 0 to 27, with higher scores indicating more
depressive symptoms. The German version of the PHQ is found to be a reliable and valid measure for
depression in patients with COPD [11].
2.4. Procedure
Patients filled out all self-report measures (CAF, CAT, BDI/TDI, SGRQ, and PHQ-9) at the start,
at the end, and six months after the pulmonary rehabilitation program. FEV1 and 6MWT distance
were only available at the start and end of the pulmonary rehabilitation program. For a full overview
of measures available in the dataset at each measurement time, see [46].
2.5. Data Analysis
Changes in patients’ outcomes across the three measurement points were analyzed using linear
mixed models. In order to model change over time, we used fixed effects of timepoint (three levels—start
of PR, end of PR, six-month follow-up), as well as random intercept and slopes, implemented using
an unstructured variance/covariance matrix. We carried out separate analyses for the different outcome
measures (BDI, TDI, 6MWT, SGRQ, and CAT). The control variables in our analysis were gender, age,
smoking status, lung function (as measured by the FEV1% predicted), and depression (as measured by
the PHQ-9).
Impact of disease-specific fears on outcome trajectories were analyzed in a first set of models using
baseline (continuous) CAF scores and their interaction with time as a fixed predictor variable. In order
to facilitate interpretation of these continuous predictors, baseline CAF scores were standardized and
comparisons of participants scoring−1, 0, and 1 (corresponding to CAF scores 1SD below mean, at mean,
and 1SD above mean) are reported. In a second set of analyses, we included (continuous) CAF scores
as a time-varying covariate. In these analyses, CAF scores were mean centered within participants
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in order to assess effects of within-individual change in CAF scores. Scores were standardized using
baseline SD for each disease-specific fear in order to facilitate comparisons. These analyses also
included mean CAF for each participant (standardized across participants) to account for effects of
between-individual differences in CAF scores. Models were fitted separately for each CAF subscale
and each outcome variable; and corrected analyses also included additional control variables: gender,
age, smoking status, baseline lung function (FEV1% predicted), and baseline depressive symptoms
(PHQ-9). For effect plots, we opted to not only include estimated trajectories (output of the different
models), but also plotted observed data in order to provide a visual check for model fit and underlying
variability in the data.
We performed all analyses using R (lme4, lmerTest, and emmeans packages) [61–63],
using Satterthwaite’s approximation for degrees of freedom and p-values. The significance level was
set at p ≤ 0.05 (using Tukey corrections for multiple comparisons).
3. Results
3.1. Patient Characteristics
We studied an initial sample of 146 patients who participated in the STAR Study. These data
consisted a first, blinded data release from the STAR Study investigators, and no data on group allocation
was available. Patients had an average age of 57.54 years (SD = 4.38). Amongst the patients were 45.2%
active smokers and 54.8 nonsmokers with a mean of 44.39 pack years (SD = 22.80). A summary of
other patient characteristics can be found in Table 1. Age, gender, and inhaled medication use were not
associated with disease-specific fears at baseline. Exacerbation history, FEV1, 6 min walking distance,
and depressive symptoms showed associations with three or more disease-specific fears.
Table 1. Baseline characteristics of participants.
Variable N Data Association with BaselineDisease-Specific Fears p < 0.05
Age, mean (SD) 146 57.5 (4.4) ns
Gender, n (%) 146 ns
Males 98 (67)
Females 48 (33)
Smoking status, n (%) 146 SRW
Active smokers 66 (45)
Non-smokers 80 (55)
Pack years, mean (SD) 142 44.4 (22.8) ns
Exacerbation history (past year), n (%) 140 FD, FP, FSE
0 or 1 exacerbation 68 (49)
2 or more exacerbations 72 (51)
Inhaled Medication, n (%) 146 ns
ICS + LABA + LAMA 64 (44)
ICS + LABA/LAMA 15 (10)
LABA + LAMA 50 (34)
LABA/LAMA monotherapy 10 (7)
SABA or no inhaled medication 7 (5)
FEV1% predicted, mean (SD) 142 55.4 (16.6) FD, FPA, FSE
6MWT, mean (SD) 144 460.8 (102.5) FD, FPA, FSE
Baseline PHQ-9, mean (SD) 138 7.9 (5.4) FD, FPA, FP, FSE, SRW
SD = standard deviation; ICS: inhaled corticosteroid; LABA: long-acting ß-agonist; LAMA: long-acting muscarinic
antagonist; SABA: short-acting ß-agonist; FEV1%: forced expiratory volume; 6MWT: Six-Minute Walking Test;
PHQ-9: Patient Health Questionnaire. FD: Fear of Dyspnea, FPA: Fear of Physical Activity, FPR: Fear of Progression,
FSE: Fear of social exclusion, SRW: Sleep-Related Worries. Differences in N are due to missing values.
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3.2. Change in Disease-Specific Fears and other Pulmonary Rehabilitation Outcomes
Patients showed significant changes on all subscales of the COPD anxiety questionnaire across
time (Table 2). Further exploration showed a significant improvement for all disease-specific fears
at the end of PR (Cohen’s d 0.48 (fear of social exclusion)–1.26 (fear of dyspnea), Figure 1). For fear
of dyspnea (d = 1.24, p < 0.0001), fear of physical activity (d = 0.75, p < 0.0001), and fear of disease
progression (d = 0.52, p = 0.0004), these improvements remained significant at 6 months follow-up,
whereas this was not the case for fear of social exclusion (d = 0.18, p = 0.3340) and sleep related worries
(d = 0.31, p = 0.0981), (Figure 1).
When controlling for covariates, the main effects of time remained significant for all CAF
subscales, and effect sizes were similar to the primary analyses: Start–End PR: d = 0.48 (fear of social
exclusion)–d = 1.26 (fear of dyspnea); Start–Follow Up: d = 0.18 (fear of social exclusion)–d = 1.25 (fear
of dyspnea); see Supplementary Table S1 for full results.
1 
 
 
 
Figure 1. Individual trajectories of dyspnea-related fears with mean trajectories (±95% CI)
superimposed.
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At the end of pulmonary rehabilitation, participants had improved on all outcomes. For our main
outcome (Symptom burden measured using CAT), participants showed an average improvement from
Start–End PR of 5.54 points (SE = 0.475, d = 1.412, p < 0.0001). At six months follow up, improvement
was reduced to 2.45 points (SE = 0.513, d = 0.625, p < 0.0001). Similar outcomes were found for
reductions in SGRQ subscales (Start–End PR: d = 0.733 (SGRQ Activity)–d = 1.144 (SGRQ Impact);
Start–Follow Up: d = 0.449 (SGRQ Activity)–d = 0.812 (SGRQ Impact)). Six-minute walking distance
was improved by 81.5 m at the end of PR (SE = 9.06, d = 1.19, p < 0.0001). Furthermore, participants
reported a change in impact of dyspnea on daily living (measured using TDI), but these changes
were reduced at six months follow up. Improvements in depressive symptoms (Start–End PR: 2.87,
SE = 0.382, d = 0.919, p < 0.0001), were no longer significantly different from baseline at follow up
(0.797, SE = 0.398, d = 0.251, p = 0.1218), (Table 2). When taking control variables into account, findings
were similar for all outcome measures (see Supplementary Table S1 for full results).
Table 2. Change in disease-specific fears and other pulmonary rehabilitation outcomes.
Start PR End PR Follow-Up
Variable Mean SE Mean SE Mean SE F df p
Disease-Specific Fears (CAF)
Fear of Social Exclusion 10.74 a 0.542 9.03 b 0.555 10.09 a 0.582 8.376 (2, 146.16) 0.0004
Fear of Dyspnea 9.86 a 0.44 6.67 b 0.372 6.72 b 0.337 53.203 (2, 146) <0.0001
Fear of Physical Activity 10.4 a 0.425 7.75 b 0.413 8.22 b 0.414 31.614 (2, 145.98) <0.0001
Fear of Progression 10.90 a 0.489 8.91 b 0.488 9.25 b 0.507 14.391 (2, 146) <0.0001
Sleep-Related Worries 2.51 a 0.17 1.89 b 0.158 2.18 ab 0.16 10.759 (2, 146) <0.0001
Symptom Burden (CAT) 20.8 a 0.579 15.2 b 0.603 18.3 c 0.646 70.322 (2, 145.98) <0.0001
Quality of Life (SGRQ)
Symptoms 61.1 a 1.81 36.6 b 1.91 52.9 c 2.03 35.853 (2,142.28) <0.0001
Activity 63.8 a 1.47 52.7 b 1.62 57.0 b 2.15 16.289 (2, 144.91) <0.0001
Impact 41.8 a 1.37 27.7 b 1.44 31.8 c 1.81 39.083 (2, 145.69) <0.0001
Transition Dyspnea Index (TDI) 1.92 a 0.107 1.04 b 0.135 45.484 (1, 169.9) <0.0001
Depressive Symptoms (PHQ-9) 7.9 a 0.422 5.02 b 0.406 7.12 a 0.407 31.592 (2, 143.24) <0.0001
6 Min walking test Distance (m) 461 a 6.68 542 b 9.24 81.711 (1, 226.17) <0.0001
Note: Within a row, different subscripts (e.g., a, b, c) indicate means that show a significant (p < 0.05) difference
between Start PR, End PR or Follow-up, respectively. Means with the same subscript do not show a significant
difference between Start PR, End PR or Follow-up, respectively. Model for transition dyspnea index includes
baseline dyspnea index values as covariate. Scale ranges are 0–32 (fear of social exclusion), 0–20 (fear of dyspnea),
0–24 (fear of physical activity, fear of disease progression), 0–8 (sleep related worries), 0–40 (CAT), 0–100 (SGRQ
scales), −9–9 (TDI).
3.3. Impact of Disease-Specific Fears on Pulmonary Rehabilitation Outcomes
3.3.1. Baseline Levels of Disease-Specific Fears
Baseline levels of all disease-specific fears had a main effect on symptom burden. Fear of
progression showed the smallest association with CAT scores; with baseline fear of progression 1SD
above the mean being associated with 2.53 (1.47–3.58) points higher CAT scores. Sleep-related worries
showed the largest associations; with baseline scores 1SD above the mean being associated with 3.76
(2.82–4.71) points higher CAT scores. Associations between baseline disease-specific fears and CAT
scores were similar after PR and follow up (Figure 2). Disease-specific fears did not have different
effects at different time points (all interaction terms p > 0.32). Main effects of disease-specific fears
remained significant after inclusion of covariates, although their magnitudes were attenuated, ranging
from 1.30 (0.25–2.36) for fear of progression to 2.81 (1.87–3.74) for sleep-related worries.
Disease-specific fears had similar main effects on SGRQ symptom scores, with higher baseline
levels of disease-specific fears being associated with higher SGRQ symptom scores across all time
points. Effects ranged from 5.87 (2.50–9.25) points for participants with baseline fear of progression 1SD
above the mean to 10.39 (7.27–13.50) for sleep-related worries. After adjusting for covariates, the main
effects of disease-specific fears remained significant, but the estimates were somewhat attenuated,
ranging from 4.7 (1.27–8.12) points for fear of progression to 7.78 (4.62–10.9) for sleep-related worries.
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Baseline differences in disease-specific fears were not associated with differences in SGRQ activity
scores at baseline. However, differences in SGRQ activity scores emerged after PR and at follow-up,
resulting in reduced treatment efficacy for participants with higher disease-specific fears (Figure 3).
Differential treatment effects were similar for all disease-specific fears, with smallest effects for fear
of dyspnea, and largest effect for fear of physical activity. Participants with average fear of dyspnea
improved 11.09 (5.05–17.13) points during PR (d = 0.74, p < 0.0001), which was reduced to 2.89
(−4.66–12.43) points (d = 0.26, p = 0.8886) for participants having fear of dyspnea 1SD above the
mean. Similarly, participants with mean levels of fear of physical activity improved 11.10 (5.15–17.06)
points during PR (d = 0.76, p < 0.0001), whereas this was reduced in participants with fear of physical
activity 1SD above the mean (1.89 (−6.52–10.3), d = 0.13, p = 0.9987). After PR, differences in SGRQ
activity scores between participants with high vs. mean levels of disease-specific fears were smallest
for sleep-related worries 6.64 (1.73–11.56) and largest for fear of physical activity 9.28 (4.53–14.03).
At follow up, we observed smallest effects for fear of dyspnea 7.93 (1.54–14.31) and largest effects
for fear of physical activity 9.91 (3.80–16.02). Adjusting for covariates, estimates were somewhat
attenuated, but remained significant. After PR, this resulted in smallest effects for fear of progression
5.59 (0.29–10.88) and largest effects for fear of physical activity 8.10 (3.04–13.17). Similar results were
obtained at follow-up (fear of progression 5.89 (0.89–12.67), fear of physical activity 8.67 (2.32–15.02).
Similar to the effects of disease-specific fears on SGRQ activity scores, baseline differences
in disease-specific fears were not associated with differences in SGRQ impact scores at baseline,
but emerged after PR and at follow-up, resulting in reduced treatment efficacy for participants with
higher disease-specific fears. In these analyses, differences in SGRQ impact scores were similar for all
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disease-specific fears, with differences between participants with high vs. mean levels of disease-specific
fears being smallest for fear of dyspnea (After PR: 7.43 (3.11–11.74), Follow Up: 6.62 (1.28–11.96)) and
largest for sleep-related worries (After PR: 9.47 (5.34–13.60), Follow Up: 8.45 (3.36–13.55)). Adjusting
for covariates, estimates where somewhat attenuated, but the effects remained significant with smallest
effects observed for fear of dyspnea (After PR: 5.95 (1.52–10.37), Follow Up: 5.26 (0.09–10.61) and largest
effects observed for sleep-related worries (After PR: 7.67 (3.30–12.03), Follow Up: 6.74 (1.52–11.96)).
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3.3.2. Associations between Changes in Disease-Specific Fears and Pulmonary
Rehabilitation Outcomes
For all disease-specific fears, participant mean levels (across all time points) were strongly
correlated with disease-specific fears at baseline (r range: 0.88–0.90), whereas baseline levels and
within-individual changes (deviation from participant mean) showed smaller correlations (ranging
from r = 0.27 (fear of social exclusion) to r = 0.52 (sleep-related worries) (see Supplementary Table S2
for full correlation table). For all disease-specific fears, both participants mean levels and individual
changes in disease-specific fears were independently associated with changes in CAT scores. Effects of
individual changes were smallest for sleep-related worries, with a 1 SD reduction leading to a 1.66
(0.84–2.47) point reduction in CAT scores. Effects were largest for fear of physical activity, with a 1 SD
reduction leading to a 2.57 (1.81–3.33) point reduction in CAT scores (Figure 4). Reductions in CAT
ranged from 1.39 (0.58–2.20) (sleep-related worries) to 2.41 (1.66–3.17) (fear of physical activity) in
analyses controlling for covariates. Across participants, effects for all disease-specific fears on CAT
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scores paralleled results of the analysis of baseline disease-specific fears, with smallest effects of fear of
progression (3.40 (2.49–4.32), and largest effects of sleep-related worries (4.62 (3.87–5.37)) (Figure 4).
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SD reduction leading to a 2.57 (1.81–3.33) point reduction in CAT scores (Figure 4). Reductions in 
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disease-specific fears leading to a reduction in S R sy pto scores ranging fro 5.31 (2.55–8.10)
(fear of physical activity) to 7.71 (5.09–10.48) (sleep-related worries). Reductions in SGRQ sy pto
scores ranged from 5.00 (1.91–8.08), (fear of physical activity) to 7.62 (4.77–10.47) (sleep-related worries)
in analyses controlling for covariates. Across participants, 1 SD higher disease-specific fear scores were
associated with higher SGRQ symptom scores, ranging from 9.52 (6.74–12.36) for social exclusion),
to 12.23 (9.69–14.73), for sleep-related worries.
For SGRQ activity scores, within-participant reductions in fear of physical activity (5.42 (2.35–8.94)),
fear of progression (4.97 (1.26–8.34)), and fear of social exclusion (3.88 (0.36–7.17)) were associated ith
improved outcomes. However, improvements in fear of dyspnea (0.81 (−3.04–4.47)) and sleep-related
worries (2.26 (−1.06–5.85)) did not show significant associations with SGRQ activity scores. Analyses
controlling for covariates showed similar results (fear of physical activity 5.80(2.40–9.59), fear of
progression 5.34 (1.84–9.25), fear of social exclusion 4.60 (0.75–8.02), fear of dyspnea 0.94 (−3.31–5.42),
sleep-related worries 2.91 (−0.80–6.33)). Across participants, all disease-specific fear scores were
associated with higher SGRQ activity scores, ranging from 5.46 (3.28–7.50)) for fear of dyspnea to 8.35
(6.35–10.43) for fear of physical activity.
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For SGRQ impact scores, within-participant reductions on all disease-specific fears were associated
with reduced impact of COPD on daily life, with associations ranging from 3.40 (0.25–6.25), for changes
in fear of dyspnea to 8.04 (5.38–10.71) for changes in fear of physical activity. Controlling for covariates
yielded similar results, with associations ranging from 4.30 (1.00–7.53) for fear of dyspnea to 8.60
(5.93–11.39) for fear of physical activity. Across participants, all disease-specific fear scores were
associated with higher SGRQ activity scores, ranging from 6.58 (4.58–8.57), for fear of dyspnea to 9.90
(8.27–11.53), for fear of physical activity.
4. Discussion
In this study, we investigated associations between disease-specific fears and changes in pulmonary
rehabilitation outcomes during a three-week inpatient rehabilitation program and at six-month follow
up. For all measurers of disease-specific fears, as well as all outcome measures, participants showed
improvement during rehabilitation. Outcomes at six-month follow-up remained improved when
compared to the start of pulmonary rehabilitation, although improvements in symptom burden and
quality of life showed significant attenuation during follow-up compared to the end of rehabilitation.
However, at six-month follow-up, depressive symptoms, fear of social exclusion, and sleep-related
worries no longer showed improvement compared to the start of PR. Finally, across all timepoints,
improvements in disease-specific fears were associated with better rehabilitation outcomes.
Notably, different disease-specific fears showed different change trajectories. We observed the
largest reductions in fear of dyspnea and fear of physical activity. Other studies have reported changes in
fear of dyspnea, fear of physical activity or related measures of fear and anxiety in the context of physical
activity during pulmonary rehabilitation [37,43,64], and have reported correlations with changes in
key outcomes of rehabilitation [37,42], but our study is the first to investigate longer-term changes in
disease-specific fears. Additionally, other researchers have argued that changes in dyspnea-specific fear
and anxiety may be a key mechanism for symptom change during pulmonary rehabilitation [42,65].
In our study, we showed that improvements in fear of physical activity were associated with improved
symptom burden and quality of life. Effects of changes of fear of dyspnea were smaller, and failed
to reach significance for the SGRQ activities subscale. The latter finding is unexpected, but could
be a result of the specific content of the SGRQ activities subscale, which mainly focuses on physical
activity. Nevertheless, in general our findings confirm previous findings on the importance of fear of
dyspnea and fear of physical activity as important contributors to symptom burden and quality of life
in individuals with COPD.
Changes in sleep-related worries and fear of social exclusion were smallest, and were no longer
significantly different from baseline when measured at follow up. Poor sleep quality and sleep disorders
are prevalent in patients with COPD, with over half of individuals with COPD reporting poor sleep
quality, which contributes to reduced quality of life [66–68]. Similarly, loneliness and feelings of social
exclusion have been documented in individuals with COPD, with similar impact on quality of life [69].
However, these issues were not an explicit target of the multicomponent pulmonary rehabilitation
program. Furthermore, a short inpatient program may have limited potential for addressing and
changing these issues. For example, although the social/group aspect of pulmonary rehabilitation has
been suggested as a beneficial treatment component [70], a change in social context and transition
back to the home context could be related to increased feelings of social exclusion. Nevertheless,
within-individual changes in sleep-related worries and fear of social exclusion were associated with
improvements in symptom burden and quality of life, highlighting the role of these fears as a potential
target for treatment in individuals with COPD.
Higher baseline levels of disease-specific fears were associated with worse symptom burden at
all time points, suggesting that the negative impact of disease-specific fears on symptoms persists
even when COPD symptoms are being treated. Furthermore, participants with higher baseline levels
of disease-specific fears showed less beneficial effects of pulmonary rehabilitation on self-reported
activity limitations (SGRQ activity and impact scales), despite an improvement in symptom burden.
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These findings suggest that disease-specific fears may be especially important for the transfer of
improvements in the rehabilitation context to activities in daily life, which has been identified as
an ongoing challenge for the efficacy of pulmonary rehabilitation [5].
Although our findings on the negative effects of baseline disease-specific fears corroborate previous
findings [37], other studies have found positive or inconsistent effects of baseline disease-specific fears
on pulmonary rehabilitation outcomes [36,40,43]. This suggests that some rehabilitation programs
may be more successful than others in mitigating effects of disease-specific fears. Although pulmonary
rehabilitation programs are similar in focusing on exercise and patient education, there are also
differences in patient or program characteristics, as well as duration or inpatient vs. outpatient setting
of programs, which could have an impact on disease-specific fears and complicate the potential for
generalization of findings to other rehabilitation programs [71,72]. For example, studies that have
reported associations between disease-specific fears and improved rehabilitation outcomes were
carried out in outpatient settings [36,40,43], whereas the current study confirms associations with
worse treatment outcomes, which were previously observed in inpatient PR programs [37]. Replication
in different settings, or direct comparisons of the efficacy of different (add on) treatment components
could inform the development of rehabilitation programs that have increased efficacy in reducing
disease-specific fears. Moreover, treatment components that explicitly target disease-specific fears
have been mostly lacking in pulmonary rehabilitation programs. Exceptions include an add-on
panic prevention program, using cognitive techniques to change catastrophic interpretations of
breathlessness [73] and a more comprehensive CBT program, which included a combination of
cognitive techniques, and exposure to feared activities to reduce fear and anxiety [74]. Further
integration of these techniques during pulmonary rehabilitation (especially during exercise training)
would be an interesting novel approach to further reduce fear of dyspnea and fear of physical
activity [75].
Differences in outcomes associated with baseline levels of disease-specific fears suggest that
assessment of disease-specific fears could be used as a basis for additional tailoring of COPD
treatment. Many rehabilitation programs already provide some tailoring, including tailoring based
on psychological needs [5,76]. As specific tailoring or treatment approaches aimed at reducing
disease specific fears are currently lacking in COPD, it can be beneficial to compare the efficacy of
existing approaches in reducing disease-specific fears, as well as explore novel tailoring approaches
incorporating disease-specific fears. In such an approach, disease-specific fears become a treatable trait,
that can be assessed and for which treatment can be incorporated in current COPD treatments [77].
There are a number of limitations which may reduce the generalizability of our findings. A first
set of limitations relates to the specific setting in which we conducted the research: a single center
offering inpatient rehabilitation. As noted above, there may be limitations to studying disease-specific
fears during inpatient rehabilitation, as this setting is very different from the home setting of patients.
Furthermore, we conducted an observational study in the context of a clinical trial that was not
explicitly aimed at changing disease-specific fears, which leaves room for alternative causal pathways.
One such potential cause of differential outcomes may be the optional treatment components that
were part of the PR program, as it is conceivable that disease-specific fears may have an impact
on the treatment components that are offered to patients. Unfortunately, we did not have data on
specific patient trajectories or treatments that were offered to individual patients. Taken together,
these limitations highlight the complexity of the relationship between disease-specific fears and PR
outcomes. Additional research on disease-specific fears in other treatment settings, or research focusing
on the effects of specific treatment components may be needed to clear up some of this complexity.
A further limitation is the use of a subsample of an ongoing clinical trial: care in clinical trials may differ
from usual care, which may have an impact on the role of disease-specific fear on outcomes achieved
in this setting. Furthermore, the use of a limited dataset (data release with 146 completers) and the
lack of information on treatment allocation may have reduced power. A final limitation relates to the
measurement of disease-specific fears. There is currently no gold standard measure to assess these
J. Clin. Med. 2019, 8, 1460 13 of 17
fears, and information on the clinical significance of changes in disease-specific fears (i.e., minimal
clinically important difference) is lacking, which at present limits the use of these measures for routine
clinical purposes.
5. Conclusions
Disease-specific fears improve over the course of rehabilitation, with changes in fear of dyspnea,
fear of physical activity, and fear of disease progression remaining improved at six-month follow-up.
For all disease-specific fears, improvements are associated with improvements in symptom burden
and quality of life, but baseline levels of disease-specific fears continue to exert their impact
across rehabilitation and follow up. These findings suggest that treatments which further reduce
disease-specific fears would be beneficial in individuals with COPD, and may improve the impact of
pulmonary rehabilitation on health status and quality of life.
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